Preview Mode Links will not work in preview mode

This Week in Cardiology

Nov 11, 2022

AHA 2022 Part 1: ISCHEMIA-EXTEND, STRONG-HF, chlorthalidone vs HCTZ, experts vs practitioners; torsemide vs furosemide; and TG lowering are discussed by John Mandrola, MD, in this week’s podcast.

This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:

I. AHA Meta-comments


- ISCHEMIA-EXTEND: Conservative Stable CAD Management Holds Up

- Survival After Invasive or Conservative Management of Stable Coronary Disease


- Rapidly, Fully Optimize HF Meds After Hospital Discharge: STRONG-HF

- STRONG HF: More Beats Less After Discharge for Heart Failure

- Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial


- Diuretic Agents Equal to Prevent CV Events in Hypertension: DCP

- HCTZ vs Chlorthalidone -- A Win for Practicing Doctors and Science


- No Survival Advantage for Either Torsemide or Furosemide in HF: TRANSFORM-HF


- Triglyceride Lowering Fails to Show CV Benefit in Large Fibrate Trial

- Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact